Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management.

Striebel JM, Bhargava R, Horbinski C, Surti U, Dabbs DJ.

Am J Clin Pathol. 2008 Mar;129(3):383-90. doi: 10.1309/KFKDNK8CENVN24VU.

PMID:
18285260
[PubMed - indexed for MEDLINE]
Free Article
2.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force.

J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.

PMID:
16813731
[PubMed - indexed for MEDLINE]
3.

HER2 status in breast cancer--an example of pharmacogenetic testing.

Kroese M, Zimmern RL, Pinder SE.

J R Soc Med. 2007 Jul;100(7):326-9. Review.

PMID:
17606754
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

[Diagnosis of HER2 gene amplification in breast carcinoma].

Couturier J, Vincent-Salomon A, Mathieu MC, Valent A, Bernheim A.

Pathol Biol (Paris). 2008 Sep;56(6):375-9. doi: 10.1016/j.patbio.2008.03.009. Epub 2008 May 5. Review. French.

PMID:
18456424
[PubMed - indexed for MEDLINE]
5.

Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.

Ross JS.

Drug News Perspect. 2009 Mar;22(2):93-106. doi: 10.1358/dnp.2009.22.2.1334452. Review.

PMID:
19330168
[PubMed - indexed for MEDLINE]
6.

Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).

Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, Tokuda Y, Watanabe T, Toi M, Hasegawa T, Osamura RY.

Breast Cancer. 2001;8(4):316-20. Review.

PMID:
11791124
[PubMed - indexed for MEDLINE]
7.

The use of HER2 testing in the management of breast cancer.

Ravdin P.

Semin Oncol. 2000 Oct;27(5 Suppl 9):33-42. Review.

PMID:
11049055
[PubMed - indexed for MEDLINE]
8.

Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing.

Hicks DG, Kulkarni S.

Arch Pathol Lab Med. 2008 Jun;132(6):1008-15. doi: 10.1043/1543-2165(2008)132[1008:TAATFE]2.0.CO;2. Review.

PMID:
18517261
[PubMed - indexed for MEDLINE]
9.

HER2 testing in gastric cancer.

Albarello L, Pecciarini L, Doglioni C.

Adv Anat Pathol. 2011 Jan;18(1):53-9. doi: 10.1097/PAP.0b013e3182026d72. Review.

PMID:
21169738
[PubMed - indexed for MEDLINE]
10.

Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.

Chorn N.

Oncol Nurs Forum. 2006 Nov 3;33(2):265-72. Review.

PMID:
16518442
[PubMed - indexed for MEDLINE]
11.

Prognostic and predictive value of HER2/neu oncogene in breast cancer.

Masood S, Bui MM.

Microsc Res Tech. 2002 Oct 15;59(2):102-8. Review.

PMID:
12373720
[PubMed - indexed for MEDLINE]
12.

Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.

Lee JA, Shaheen M, Walke T, Daly M.

Expert Rev Pharmacoecon Outcomes Res. 2011 Jun;11(3):325-41. doi: 10.1586/erp.11.25. Review.

PMID:
21671702
[PubMed - indexed for MEDLINE]
13.

Emerging technologies for assessing HER2 amplification.

Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, van de Vijver M.

Am J Clin Pathol. 2009 Oct;132(4):539-48. doi: 10.1309/AJCPV2I0HGPMGBSQ. Review.

PMID:
19762531
[PubMed - indexed for MEDLINE]
Free Article
14.

[Assessment of HER2 status in breast cancer].

Penault-Llorca F, Cayre A.

Bull Cancer. 2004 Dec 1;91 Suppl 4:S211-5. Review. French.

PMID:
15899610
[PubMed - indexed for MEDLINE]
15.

HER2 testing recommendations in Australia.

Bilous M; HER2 Testing Advisory Board.

Pathology. 2001 Nov;33(4):425-7. Review.

PMID:
11827407
[PubMed - indexed for MEDLINE]
16.

Current status of HER2 testing.

Di Leo A, Dowsett M, Horten B, Penault-Llorca F.

Oncology. 2002;63 Suppl 1:25-32. Review.

PMID:
12422052
[PubMed - indexed for MEDLINE]
17.

Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).

Albanell J, Andreu X, Calasanz MJ, Concha A, Corominas JM, García-Caballero T, López JA, López-Ríos F, Ramón y Cajal S, Vera-Sempere FJ, Colomer R, Martín M, Alba E, González-Martín A, Llombart A, Lluch A, Palacios J.

Clin Transl Oncol. 2009 Jun;11(6):363-75. Review.

PMID:
19531451
[PubMed - indexed for MEDLINE]
18.

HER2/neu in the management of invasive breast cancer.

Meric F, Hung MC, Hortobagyi GN, Hunt KK.

J Am Coll Surg. 2002 Apr;194(4):488-501. Review. No abstract available.

PMID:
11949754
[PubMed - indexed for MEDLINE]
19.

HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.

Hicks DG, Kulkarni S.

Am J Clin Pathol. 2008 Feb;129(2):263-73. doi: 10.1309/99AE032R9FM8WND1. Review.

PMID:
18208807
[PubMed - indexed for MEDLINE]
Free Article
20.

[In situ hybridization in clinical pathology. Significance of polysomy 17 for HER2 determination and genetic tumor heterogeneity in breast cancer].

Gaiser T, Rüschoff J, Moll R.

Pathologe. 2012 Nov;33 Suppl 2:307-10. doi: 10.1007/s00292-012-1663-z. Review. German.

PMID:
23052344
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk